BIOMAT Database Logo BIOMAT Database Logo

HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. 1995

R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, USA.

OBJECTIVE To characterize the HER-2/neu oncogene in head and neck squamous cell carcinoma (HNSCC) cell lines and tumor tissue specimens. METHODS Molecular analysis of HER-2/neu oncogene amplification and expression in HNSCC cell lines by Southern, Northern, and Western blot techniques, and HER-2/neu oncoprotein expression in HNSCC tumor tissue sections by immunohistochemical analysis. METHODS Eleven HNSCC cell lines, eight paired samples of frozen HNSCC tumor tissue specimens and adjacent nonmalignant mucosa, and 38 paraffin-embedded slides derived from HNSCC tumor specimens (including those from which the cell lines were derived) were analyzed. RESULTS Southern blot analysis showed twofold HER-2/neu gene amplification in two (18%) of the 11 HNSCC cell lines, MDA-1386 and Tu-167. Northern blot analysis showed messenger RNA overexpression in the same two cell lines, and to a lesser degree in MDA-1483. Western blot analysis showed high levels of HER-2/neu oncoprotein expression in two (18%) of the 11 cell lines (MDA-1386 and Tu-167), a moderate level of protein expression in one cell line (9%) (MDA-1483), and low levels of protein expression in eight cell lines (73%). Some HER-2/neu protein expression was seen in all of the HNSCC cell lines. Immunohistochemical analysis of the tumor tissue sections from which the cell lines were derived corroborated the Western blot results. Western blot analysis of frozen primary tumor specimens showed HER-2/neu oncoprotein overexpression in two (25%) of eight specimens. Immunohistochemical analysis showed high levels of protein expression in six (16%) of the 38 tumor tissue slides, moderate levels in 12 (31%), and low levels in 20 (53%). CONCLUSIONS The HER-2/neu oncogene is overexpressed in a subset of HNSCC tumors and cell lines. The results from Western blot and immunohistochemical analyses underscore a variable HER2/neu oncoprotein expression in HNSCC. Gene amplification was observed in a few of the cell lines, suggesting a potential mechanism of oncoprotein overexpression. Messenger RNA overexpression, however, can be seen in the absence of gene amplification, indicating that transcriptional or posttranscriptional control mechanisms must be involved. Further studies are indicated to determine the biologic role of HER-2/neu expression in the clinical progression of these lesions and to further define the molecular basis regulating its expression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.
July 2007, Head & neck,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Expression of HER-2/neu in Oral Squamous Cell Carcinoma.
May 2020, Asian Pacific journal of cancer prevention : APJCP,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
January 2007, Urology journal,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
February 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma.
April 1996, The Annals of otology, rhinology, and laryngology,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
[Oncogene her-2/neu and ovarian carcinoma: intraperitoneal cellular immunotherapy].
January 2000, Annales de pathologie,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
[HER-2/neu oncogene as prognostic factor in breast carcinoma].
January 1992, Pathologica,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
Oncogene amplification in squamous cell carcinoma of the head and neck.
December 1990, Archives of otolaryngology--head & neck surgery,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
HER-2/neu oncogene sequence revisited.
December 2002, Journal of the National Cancer Institute,
R N Beckhardt, and N Kiyokawa, and L Xi, and T J Liu, and M C Hung, and A K el-Naggar, and H Z Zhang, and G L Clayman
DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder.
November 1991, The Journal of urology,
Copied contents to your clipboard!